Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-Cytokine for Melanoma
- Development stage
- Preclinical
- Lead developer
- Kyttaro
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intratumoral, Intravenous, Subcutaneous
01
Overview
**MSC-Cytokine for Melanoma** is an early research-stage engineered mesenchymal stromal cell therapy from Kyttaro Therapeutics. The product consists of genetically modified mesenchymal stromal cells designed to secrete interleukin-7 and interleukin-12, using the cells as a tumor-directed cytokine-delivery vehicle intended to stimulate antitumor immune activity in melanoma. The Kyttaro pipeline lists the melanoma program as R&D-stage; no clinical trial, dose regimen, route of administration, or manufacturing partner was identified in the provided public-source context.
- Other names
- MSC-Cyt (IL-7/IL-12)
02
Targets
IL-12R (Interleukin-12 receptor)IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on MSC-Cytokine for Melanoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-Cytokine for Melanoma.